Introduction
============

Carcinosarcoma, also referred to as malignant mixed Müllerian tumor (MMMT), which contains both carcinomatous and sarcomatous elements, generally arises in the female genital tract. Extragenital carcinosarcoma is rare and several cases of carcinosarcoma occurring in the retroperitoneum ([@b1-mco-0-0-1711]), mesentery ([@b2-mco-0-0-1711],[@b3-mco-0-0-1711]) and lesser omentum ([@b4-mco-0-0-1711]) have been reported to date. However, carcinosarcoma arising from the Douglas pouch is extremely rare, with only 2 such cases reported in the English literature ([@b5-mco-0-0-1711],[@b6-mco-0-0-1711]).

The aim of the present study was to present a case of carcinosarcoma arising from the Douglas pouch and discuss the clinicopathological characteristics and therapeutic management of this rare tumor.

Case report
===========

A 73-year-old woman (gravida 6, para 4) presented with fever and lower abdominal pain. The patient\'s medical history included hypertension and hyperlipidemia. A vaginal examination revealed purulent discharge and a fist-sized soft tumor was palpable in the pelvis. Pelvic ultrasound examination revealed an irregular round mosaic mass \>10 cm in greatest diameter. Magnetic resonance imaging examination of the pelvis revealed a large pelvic mass with abscess formation invading the rectum, with enlarged bilateral iliac lymph nodes. The serum carbohydrate antigen 125 level was 334 U/ml. A computed tomography scan confirmed enlargement of Virchow\'s lymph node. Since left ovarian cancer was suspected, laparotomy was performed. Although a left ovarian abscess and a Douglas pouch mass were detected in the abdominal cavity, there was no obvious tumor involvement of the bilateral ovaries or uterus. Peritoneal dissemination, including the omentum, was not observed. The patient underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy and tumor debulking, with a reduction rate of \~30%, as the tumor firmly adhered to the pelvic wall, uterus and rectum. Sigmoid colostomy was also performed to prevent obstructive ileus due to the deep and wide rectal invasion. The patient received several courses of combination chemotherapy with paclitaxel, carboplatin and bevacizumab, according to the standard adjuvant chemotherapy guidelines for ovarian cancer ([@b7-mco-0-0-1711]). Each drug was administered triweekly: Paclitaxel, 175 mg/m^2^; carboplatin, AUC 6 and bevacizumab, 15 mg/kg. After three courses, complete remission was achieved and no recurrence has been detected during follow-up to date (data not shown).

Histologically, the pelvic tumor was composed of a mixture of serous carcinoma and spindle-cell sarcoma with necrosis and hemorrhage. The epithelial component displayed tubular, papillary, or cribriform proliferation of severely atypical cells with mitotic figures, mimicking ovarian high-grade serous carcinoma. The adjacent stromal component consisted of atypical spindled cells with severe nuclear atypia and mitotic figures. The spindle-cell sarcoma element partly exhibited myxomatous changes. Although a left ovarian abscess was identified, tumor cells were not detected in the bilateral ovaries or uterus.

Immunohistochemically, the serous carcinoma component was positive for cytokeratin (CK)7, Wilms\' tumor-1 and p53 (the null type), while CDX-2 and CK20 were negative. The spindle-cell sarcoma component was positive for vimentin and α-smooth muscle actin. p53 was also positive (the null type) in the sarcoma component. The case was diagnosed as carcinosarcoma of the homologous type primarily derived from the peritoneum in the Douglas pouch.

Discussion
==========

A rare case of primary peritoneal carcinosarcoma of the homologous type arising in the Douglas pouch was encountered and successfully treated with adjuvant chemotherapy, including a molecular-targeting agent.

Carcinosarcoma of the female genital tract, also referred to as MMMT, is divided into two groups, homologous and heterologous types, according to the histological characteristics of the sarcomatous element. The malignant mesenchymal component of the tumor is described as homologous or heterologous ([@b8-mco-0-0-1711]). The homologous type consists of tissues indigenous to Müllerian structures (e.g., resembling endometrial stromal sarcoma, fibrosarcoma, or leiomyosarcoma). If the sarcomatous component contains elements not normally found in the Müllerian structures (e.g., cartilaginous, osseous, or rhabdomyocytic), it is described as heterologous. The epithelial and mesenchymal elements in these tumors are generally randomly admixed. Both are high-grade, while the mesenchymal component may occasionally be composed of relatively bland spindle cells. In the present case, the epithelial component resembled ovarian high-grade serous carcinoma and the mesenchymal element mimicked leiomyosarcoma. Thus, the patient was diagnosed with carcinosarcoma of the homologous type.

Carcinosarcoma is an aggressive tumor and it may be resistant to conventional chemotherapy. Since primary peritoneal carcinosarcoma is rare, there are no established treatment strategies or guidelines and treatment decisions are based on each individual diagnosis. In the present case, combination chemotherapy with paclitaxel and carboplatin was initiated, which is commonly used for epithelial ovarian cancer. The molecular-targeting agent bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), was also included in the treatment regimen. This regimen was proven to be markedly effective and a complete response was achieved after three courses. The patient has remained disease-free by continuing this regimen. To the best of our knowledge, this appears to be the first medical case report of Douglas pouch carcinosarcoma successfully treated with chemotherapy including anti-VEGF therapy with bevacizumab.

Some reviews have been published on the primary treatment and prognostic factors of Müllerian carcinosarcomas ([@b9-mco-0-0-1711],[@b10-mco-0-0-1711]). Based on these reviews, platinum-based chemotherapy is the mainstay of adjuvant systemic treatment, and the addition of paclitaxel or ifosfamide to platinum is recommended as first-line treatment. However, these cases include several carcinosarcoma cases of the ovaries and fallopian tubes. Thus, selective analyses of primary peritoneal carcinosarcoma cases are needed in future studies.

Extragenital carcinosarcomas mostly occur in the pelvic peritoneum ([@b11-mco-0-0-1711]), whereas they rarely develop in the retroperitoneum ([@b1-mco-0-0-1711]), mesentery ([@b2-mco-0-0-1711],[@b3-mco-0-0-1711]) and lesser omentum ([@b4-mco-0-0-1711]). Carcinosarcoma arising from the Douglas pouch is extremely rare, this being the third case reported in the English literature to date ([@b5-mco-0-0-1711],[@b6-mco-0-0-1711]). Due to its rarity, there are difficulties with making an accurate preoperative diagnosis of primary peritoneal carcinosarcoma. In the present case, the preoperative diagnosis was left ovarian cancer and the tumor was found to be located in the Douglas pouch after laparotomy. Clinicians must be aware of extragenital malignancies when a large pelvic mass is detected clinically.

The etiology and tumorigenesis of primary peritoneal carcinosarcoma remain unknown. The origin of the present tumor was hypothesized to be peritoneal multipotent cells or misplaced Müllerian duct remnants in the Douglas pouch ([@b12-mco-0-0-1711]). However, further studies are required to elucidate its cellular origin.

The principal treatment for primary peritoneal carcinosarcoma is optimal surgery and subsequent systemic chemotherapy. Despite its rarity, the accumulation of more clinical cases is crucial for elucidating the clinicopathological characteristics of this rare tumor and establishing effective therapeutic strategies.
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![T2-weighed magnetic resonance imaging of the pelvis revealed a large pelvic solid tumor. Arrows indicate the tumor, whereas the high-intensity area appears to correspond to abscess formation. The uterus was compressed by the pelvic tumor (asterisk).](mco-09-05-0485-g00){#f1-mco-0-0-1711}

![(A and B) On examination of hematoxylin and eosin-stained sections, the pelvic tumor consisted of atypical epithelial elements and atypical spindle cell components. (C) High-power view of the epithelial component. The atypical epithelial component displayed solid and tubular proliferation of cells with severe nuclear atypia and mitotic figures, mimicking ovarian high-grade serous carcinoma. (D) High-power view of the mesenchymal component. The stromal component consisted of atypical spindle cells with severe nuclear atypia and mitotic figures, mimicking leiomyosarcoma. Myxomatous changes were also partly observed. Scale bar, (A) 1 mm, (B) 200 µm and (C and D) 50 µm.](mco-09-05-0485-g01){#f2-mco-0-0-1711}

![Immunohistochemical analyses of the pelvic tumor. As shown in the lower right panel, the epithelial component was positive for Wilms\' tumor (WT)-1 and negative for CDX-2. The mesenchymal element was positive for α-smooth muscle actin (SMA). p53 was positive (null type) in both components. Scale bar, 200 µm (except for WT-1: 100 µm). H&E, hematoxylin and eosin staining.](mco-09-05-0485-g02){#f3-mco-0-0-1711}
